From diagnosis methods to management of comorbid infections, new lung cancer protocols adaptable for various conditions ...

Virtual echocardiography screening tool scores calculated via algorithm matched manually calculated scores and are promising ...

Management of chronic thromboembolic pulmonary hypertension (CTEPH) includes multimodal therapy that depends on expert centres' experience.1,2 Guidelines advocate for pulmonary endarterectomy (PEA) to ...

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure ...

There is broad consensus that the overall body of evidence shows lowering LDL (low-density lipoprotein) cholesterol provides both statistically ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile.

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

Experts from the life sciences industry have shared key insights into how healthcare innovation is changing and the next wave of medicines.The ...